Biostatistical analysis is integral to pharmacovigilance and clinical drug development. From designing clinical trials with appropriate safety endpoints to evaluating post-marketing safety signals using disproportionality analysis, biostatistics provides the quantitative foundation for safety decisions. Regulatory authorities — both EMA and FDA — expect that safety data is analyzed using validated statistical methods aligned with ICH E9 (Statistical Principles for Clinical Trials).
This article covers the role of biostatistics in clinical trial safety analysis, study design, and exploratory pharmacovigilance analytics.
Statistical Analysis of Clinical Trial Safety Data
Role of Biostatistics in Safety Assessment
Clinical trial safety analysis goes beyond simply counting adverse events. Biostatistical methods are needed to:
- Quantify safety endpoints: Calculate incidence rates, relative risks, and confidence intervals for adverse events across treatment groups
- Identify safety signals in trial data: Detect statistically significant differences in adverse event rates between drug and comparator arms
- Support regulatory submissions: Generate the tables, listings, and figures (TLFs) required for clinical study reports (CSRs) and regulatory dossiers
- Contribute to benefit-risk assessment: Provide the quantitative safety data that feeds into integrated benefit-risk analyses for PSURs, DSURs, and RMPs
Key Components
Statistical Analysis Plan (SAP) Development
Per ICH E9, the SAP should be developed before database lock and describe:
- Safety analysis populations (safety set, per-protocol set)
- Methods for summarizing adverse events (incidence rates, exposure-adjusted rates)
- Subgroup analyses for safety (age, gender, hepatic/renal function, comorbidities)
- Methods for handling missing data
- Multiplicity adjustments for key safety endpoints
Data Analysis Execution
Depending on the study design and safety endpoints, appropriate statistical methods include:
- Descriptive statistics: Incidence tables, exposure-adjusted incidence rates (per patient-year), time-to-event analyses
- Survival analysis: Kaplan-Meier estimates and Cox proportional hazards models for time-to-first-event safety endpoints
- Logistic regression: For binary safety outcomes (e.g., occurrence of a specific SAE)
- Longitudinal models: Mixed-effects models for repeated safety measurements (e.g., liver function tests, QTc interval)
- Meta-analysis: For integrating safety data across multiple trials (per ICH E9(R1) addendum on estimands)
Regulatory-Ready Outputs
Statistical outputs for regulatory submissions must be:
- Traceable (from raw data through analysis code to final output)
- Reproducible (another statistician can replicate the results)
- Quality-controlled (independent statistical QC with documented review)
- Formatted per regulatory expectations (CDISC standards for FDA submissions, EMA submission format)
Study Design Consultation
Why Biostatistics Matters in Study Design
Engaging a biostatistician during the study design phase ensures that clinical trials are:
- Adequately powered to detect clinically meaningful safety differences
- Properly randomized to minimize bias in safety comparisons
- Designed with appropriate safety endpoints that regulators expect to see
- Equipped with interim analysis rules that allow early safety assessment without compromising trial integrity
Key Design Considerations
Sample Size Calculation for Safety
While efficacy endpoints typically drive sample size, safety considerations matter:
- Is the sample size sufficient to detect rare but serious adverse events?
- For products with known class effects (e.g., cardiotoxicity with certain oncology drugs), has the trial been powered to assess these specific safety endpoints?
- Per ICH E1A, for chronic conditions, regulators expect safety data from at least 1,500 patients, with 300–600 exposed for 6+ months and 100 for 12+ months
Randomization Design
- Stratified randomization: Ensures balance across key prognostic factors that may affect safety (e.g., age, disease severity, concomitant medications)
- Block randomization: Maintains balance within centers or time periods
- Methods must be pre-specified and documented per ICH E9
Interim Safety Analysis and Data Monitoring
- Data Safety Monitoring Board (DSMB): Independent committee that reviews unblinded safety data at pre-specified intervals
- Stopping rules: Statistical boundaries for stopping the trial early if the safety profile is unacceptable (e.g., O'Brien-Fleming boundaries for group sequential designs)
- Alpha spending functions: Control for Type I error when multiple interim analyses are planned
Exploratory and Post-Marketing Safety Analytics
Beyond Protocol-Specified Analyses
After the primary analysis, additional statistical work may be needed for:
Subgroup Analyses
Evaluating safety across patient subpopulations (age groups, gender, ethnicity, comorbidities, concomitant medications). Important caveats:
- Subgroup analyses are exploratory by nature and should be interpreted cautiously
- Multiple comparisons increase the risk of false positives — statistical methods for multiplicity adjustment should be applied
- Results should be used for hypothesis generation, not for definitive safety conclusions
Signal Detection in Pharmacovigilance Databases
Disproportionality analysis methods used for post-marketing signal detection, as referenced in EMA GVP Module IX:
- Proportional Reporting Ratio (PRR): Compares the proportion of reports for a specific drug-event combination against all other drugs
- Reporting Odds Ratio (ROR): Similar to PRR but expressed as an odds ratio
- Bayesian Confidence Propagation Neural Network (BCPNN): Uses Bayesian methods with an Information Component (IC) measure
- Multi-item Gamma Poisson Shrinker (MGPS): FDA's preferred method, produces Empirical Bayesian Geometric Mean (EBGM) scores
Each method has strengths and limitations. No single method is sufficient — regulatory expectations favor using multiple methods and interpreting results in clinical context.
Post-Marketing Data Evaluation
Statistical support for:
- PASS study design and analysis
- Effectiveness studies for risk minimization measures per GVP Module XVI
- Registry data analysis
- Real-world evidence studies supporting safety assessments
Statistical Support for Regulatory Documents
- PSUR statistical sections: exposure calculations, incidence rate analyses, signal detection statistics
- DSUR safety data summaries and trend analysis
- RMP safety specification: quantification of identified and potential risks
Conclusion
Biostatistical analysis underpins every safety decision in clinical development and post-marketing pharmacovigilance. From designing trials that can detect meaningful safety signals (ICH E9) to evaluating post-marketing disproportionality data (GVP Module IX), rigorous statistical methods are essential for protecting patients and satisfying regulatory expectations.
NextPV partners with experienced biostatisticians to provide analytical support across the full drug lifecycle — from study design consultation through post-marketing safety analytics — ensuring that every analysis meets regulatory standards and supports informed benefit-risk decisions.